The Envision Pharma Group, a global technology-enabled scientific communications organization, announced today that David Thompson who is currently its Chief Commercial Officer is to become the new Chief Executive Officer to coincide with the appointment of its current CEO, Brian Hepburn – to the position of Executive Co-Chair for the Group. Both David and Brian will assume their new roles from January 1, 2020.
David said, “I am honored and truly excited to be taking on the role of CEO for the Envision Pharma Group. The Group has been immensely successful through its unique business model of combining strategic data-centric scientific services with best-in-class technology solutions, such as the gold standard publication planning tool, Datavision. I look forward to continuing that journey through organic growth with a focus on expanding our medical affairs value proposition via the iEnvision platform. We also plan to grow our footprint through strategic acquisitions for key adjacent services. Undoubtedly we have a unique opportunity to provide market-leading solutions (through a combination of world class services and technology enablement) to our client base – which will positively impact the effective and efficient dissemination of NCE data to HCPs, payors, and patients alike.”
David joined the organization as part of Envision’s acquisition of Alligent Biopharm Consulting LLC, in September of 2015. Since then David has been instrumental in expanding the Group’s multichannel medical communication capabilities, fully aligning with the medical strategy and data dissemination core competences of Envision. He will continue to drive Envision’s goal of being seen as a strategic partner of choice for the medical affairs function within our biopharmaceutical and medical device client base. David is a 24-year veteran of the pharma services industry, having spent 15 of those years in the United States. In this role he will be based out of our UK, Horsham offices.
Brian, founder CEO from 2001, will continue to provide strategic direction and management support for the Group. He will maintain an active role driving the culture and company ethos for the ever-expanding team – which to date has been instrumental in creating one of the world’s preeminent medical affairs-focused outsourced pharma technology and services organizations.
“I can think of no one better to take over the mantle of the CEO for the Group,” added Brian. “David has been with the organization for 4 years now and truly understands its DNA, which is often the biggest challenge for any incoming CEO. In addition, he brings an energy and ‘can-do’ attitude to the table which will ensure we continue to innovate and challenge the norm. This planned transition has been in the making for some time now and I look forward to working with him closely on this new phase of the journey for Envision.”
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions that have applicability across many areas of medical affairs and related functional responsibility. Envision Pharma Group provides services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies.
Envision has twelve offices: four in the United Kingdom – Horsham, Wilmslow, Bishop’s Stortford, and London; one in Serbia – Subotica; one in Hungary – Szeged; four in the United States – Philadelphia, PA, Fairfield, CT, Warren, NJ, and Glastonbury, CT; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs 730 team members, including more than 250 highly qualified and experienced in-house medical writers and 190 technology solutions team members who provide software development and customer support.
Brian Hepburn (left), Envision Pharma Group Executive Co-Chair, and David Thompson, Chief Executive Officer (right)
Contact person: Marsha Caplin
Company: Envision Pharma Group
Company URL: www.envisionpharmagroup.com
Address: Envision House, 5 North Street, Horsham, Sussex, UK
Phone: 01403 322000